The steps required for successful market access.
Interview with Pfenex explores biosimilars in USA
Roche’s Erivedge is latest cancer drug to fall foul of NICE number-crunching.
Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
The factors shaping the healthcare landscape in emerging markets.
Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
Cost of Novartis’ revolutionary therapy is obstacle, says CMO.